TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02526979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study: NCT03570996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane catheter
Description: TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
Study: NCT04536246

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction
Description: Comparator for New Reconstruction Technique
Study: NCT03113292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercises
Description: The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
Study: NCT03377023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous nivolumab every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Intravenous nivolumab every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Intravenous nivolumab every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous ipilimumab every 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Intravenous ipilimumab every 6 weeks.
Study: NCT04067726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is commercially available and will be provided at no cost to participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: -Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Study: NCT02015793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for adalimumab
Description: Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
Study: NCT04659733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
Study: NCT04067726

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: -Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Study: NCT02832609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine
Description: measurements after 30 minutes in complete supine position
Study: NCT03377023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Intravenous ipilimumab every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
Study: NCT01837160

Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Echocardiography.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Echocardiography.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Echocardiography.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Echocardiography.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Echocardiography.

Intervention type: RADIATION
Intervention: CT-coronary angiogram scan
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.

Intervention type: RADIATION
Intervention: CT-coronary angiogram scan
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.

Intervention type: RADIATION
Intervention: CT-coronary angiogram scan
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.

Intervention type: RADIATION
Intervention: CT-coronary angiogram scan
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.

Intervention type: RADIATION
Intervention: CT-coronary angiogram scan
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.

Intervention type: PROCEDURE
Intervention: Aortic Valve Replacement
Description: For AVR (already scheduled prior to enrollment)
Study: NCT02395861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuro-electrophysiologic analyses
Description: mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
Study: NCT01984697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Description: V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Description: V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Description: V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Study: NCT04347447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All groups will complete a supervised 12-week resistance training protocol, 3 days per week.
Study: NCT01984697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Description: V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Description: V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Study: NCT03070496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECG
Description: ECG will be performed at 6 months after myocardial infarction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: Patients will pass a quality of life questionnaire at 12 months after myocardial infarction
Study: NCT03308825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine
Description: 0.25 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01878929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allergen(Tree, Grass, Weeds)
Description: Greer is manufacture of all allergen extract used in this study.
Study: NCT03500055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Closure Bundle
Description: Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
Study: NCT02644590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Detailed in arm description
Study: NCT03247790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study: NCT02347644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview
Description: Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:~* No perception of any alcohol consumption problem~* Realization of alcohol consumption problem with no corresponding action
Study: NCT01094132

Intervention type: DEVICE
Group type: OTHER
Intervention: Multispectral Digital Colposcope (MDC)
Description: The MDC has 2 components: an optical probe \& a multispectral colposcope. The optical wand makes use of fluorescence \& reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer \& healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence \& polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.~This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.~All study subjects will receive this same intervention.
Study: NCT03544320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitoring-Wrist worn wearable
Description: Participants wear an activity monitor on their wrist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitoring-Waist-worn wearable
Description: Participants wear an activity monitor on their waist.
Study: NCT04067726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Study: NCT02956642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Livongo Health System
Description: Participants will be asked to use the Livongo Health System to manage their blood glucose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iHealth Glucose Meter
Description: Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
Study: NCT02802163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Induction Phase: Carfilzomib will be administered at 20 mg/m\^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m\^2 or 36 mg/m\^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
Study: NCT06064084

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test 50g

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test 50g

Intervention type: OTHER
Intervention: Intravenous isoglycaemic glucose clamp
Description: Intravenous isoglycaemic glucose clamp

Intervention type: OTHER
Intervention: Intravenous isoglycaemic glucose clamp
Description: Intravenous isoglycaemic glucose clamp

Intervention type: OTHER
Intervention: Liquid Mixed meal test
Description: Liquid Mixed meal test 520 kcal
Study: NCT03092323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
Study: NCT06064084

Intervention type: OTHER
Intervention: Liquid Mixed meal test
Description: Liquid Mixed meal test 520 kcal
Study: NCT03033654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen, Actinica
Description: Two Consecutive Sunscreen Applications
Study: NCT00290862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Vertebral Augmentation of compression fractures
Description: Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Vertebral Augmentation of compression fractures
Description: Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
Study: NCT01855854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
Study: NCT02481284

Intervention type: DEVICE
Intervention: Laser Doppler perfusion imaging
Description: LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
Study: NCT05983328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUYPS-1 one tablet
Description: After 7-day washout time, subjects will receive HUYPS-1 1 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUYPS-1 nine tablets
Description: After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
Study: NCT04067726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core needle biopsy
Description: Baseline and 12 months

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Core needle biopsy
Description: Baseline and 12 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Baseline and 12 months

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw
Description: Baseline and 12 months
Study: NCT04532619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathering Through Change
Description: Fathering Through Change is an adaptation of Parent Management Training Oregon. This pilot provides a limited version of Fathering Through Change via text messaged and emailed weekly video content and includes individual coaching calls.
Study: NCT03643133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifamurtide
Description: 48 doses overall over 36 weeks

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EI or M-API regimen depending on patient age
Description: M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days
Study: NCT01628120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: Subcutaneous(SC) injection
Study: NCT03902275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantra-Algorithm
Description: Hemotherapy based on Quantra-Algorithm
Study: NCT03643133

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EI or M-API regimen depending on patient age
Description: M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days
Study: NCT02529449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral
Study: NCT02737800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrioma aspiration
Description: Transvaginal ultrasound guided aspiration

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: endometrioma aspiration
Description: Transvaginal ultrasound guided aspiration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh agonist ( Decapeptyl )
Description: 3 monthly doses of Decapeptyl 7.5mg intramuscular
Study: NCT03902275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ROTEM-Algorithm
Description: Hemotherapy based on Basic-Algorithm
Study: NCT02737800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh agonist ( Decapeptyl )
Description: 3 monthly doses of Decapeptyl 7.5mg intramuscular

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard long stimulation protocol
Description: Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard long stimulation protocol
Description: Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard long stimulation protocol
Description: Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard long stimulation protocol
Description: Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.